3 growth shares bucking the market in 2022

Looking at the stock market charts, we might think of 2022 more as a year for ‘hope they don’t shrink’ shares rather than growth shares.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Inflation and interest rates are rising, and the economy is looking rather poorly. That means the stock market is suffering too, right? Here are three growth shares that are bucking the trend.

As for the first one, I think even Warren Buffett might approve. The billionaire investor has, after all, just bought more Occidental Petroleum stock for his Berkshire Hathaway investing company.

Money in oil

Yes, I’m talking about oil. And, specifically, BP (LSE: BP). The BP share price has climbed 22.5% so far in 2022, and it’s up 24% over the past 12 months. The FTSE 100, incidentally, has gained 1.7% over 12 months.

The outlook for BP is a far cry from its sorry state in the depths of 2020. The pandemic sent it into a slump. And then, after BP announced its Net Zero thing, investors gave it a further kicking. But since their low that year, BP shares have more than doubled.

It’s easy to say the BP share price is up only because of oil prices. That oil prices are high due to the war in Ukraine. And that once that’s over, BP will go back to being the fossil fuel pariah it deserves to be. And that may well happen.

Against that, though, is Warren Buffett. If he’s still investing in oil, he must see a profitable long-term future for the industry.

Pharma growth

GSK (LSE: GSK), previously GlaxoSmithKline, seems to have perpetually been one of those growth shares set to deliver… tomorrow. It’s drugs pipeline ran a bit thin, while some blockbuster drug patents were expiring.

And the drug development cycle is very long and costly. It takes years to turn R&D into a marketable product.

But is GSK finally hitting a new earnings growth phase to go with its new name? Well, the share price is up 10.5% so far in 2022, and up 25% over the past 12 months.

And after a few years of earnings picking up and falling back again, analysts appear optimistic. They have three years of growth penciled in, starting this year. We’ve seen a few false starts from GSK, though, and investors might fear this could be another one.

Contrarian bank

A bank? In a year when UK favourites Lloyds and Barclays are sliding? Yes, but I’m talking about Investec (LSE: INVP), which is a bit different.

Investec is a constituent of the FTSE 250, where growth shares are more typically found. It provides financial and investment services to high-value customers in South Africa and the UK. That does seem to be paying off, with earnings nearly doubling in the year to March. The company paid a 5% dividend, more than twice covered by earnings.

The Investec share price has risen 50% over the past 12 months in response. I think that’s a remarkable performance for a company in the financial sector this year, no matter what its specific business.

My trouble is I have no clear view of the outlook. Earnings have been erratic before, and the shares have been very volatile in the past few years. More research is needed.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Alan Oscroft has positions in Lloyds Banking Group. The Motley Fool UK has recommended Barclays, GlaxoSmithKline, and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »